Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Phase 2 Completed 29 enrolled TYK Medicines, Inc

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of TY-9591 tablets in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with brain or leptomeningeal metastases.

Timeline

Start: 2022-04-02
Primary completion: 2024-03-21
Completion: 2024-11-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TY-9591	Unknown	160 mg	—

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Summary

Timeline

Drugs

Indications